Orbit Discovery
Orbit was founded By Professor Terry Rabbitts and Professor Graham Ogg in 2015 as a spin-out from the University of Oxford. The company’s focus is to identify therapeutic peptides using its unique peptide display platform. In 2021 the organisation spun out its drug discovery programs and established Orbit Discovery Ltd as a therapeutic peptide drug discovery service provider. Orbit Discovery will focus on the identification of peptide therapeutics to any target that exhibits interesting biology. The company has built up extensive expertise in the purification of complex membrane proteins and aims to become the leader in identifying peptide agonists and antagonists to GPCRs. Orbit have generated technologies to significantly improve the throughput for screening biological molecules for affinity and function. Our mission is to use high throughput affinity and functional screening to address challenging targets that have been difficult to drug.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Nationally (across the country)
- Year Founded:
- 2015
About Us
Orbit was founded By Professor Terry Rabbitts and Professor Graham Ogg in 2015 as a spin-out from the University of Oxford. The company’s focus is to identify therapeutic peptides using its unique peptide display platform. In 2021 the organisation spun out its drug discovery programs and established Orbit Discovery Ltd as a therapeutic peptide drug discovery service provider.
Orbit Discovery will focus on the identification of peptide therapeutics to any target that exhibits interesting biology. The company has built up extensive expertise in the purification of complex membrane proteins and aims to become the leader in identifying peptide agonists and antagonists to GPCRs
Our History
High throughput affinity and functional screening
Orbit have generated technologies to significantly improve the throughput for screening biological molecules for affinity and function. Our mission is to use high throughput affinity and functional screening to address challenging targets that have been difficult to drug.
What We Do
Orbit Discovery offer services for the discovery of peptides and other small biologic based moieties. Our services address high throughput screening of chemical space and allow for affinity screening and functional screening using both bead based technologies and microfuidics.
These technologies have been used to identify peptides as the starting point for peptidomimetic and small molecule therapeutics ,as well as bioconjugates for cell targeting and cargo delivery. Furthermore, the functional screening capabilities has allowed us to build screening cascades for the direct identification of functional peptides, in particular against GPCR’s.
Orbits?mission is to offer our Partners solutions to identify?therapeutic?candidates by adopting high?throughput affinity and functional screening.
Affinity Screening Service
A bead based peptide display engine, using FACS, allows for faster peptide discovery by binding affinity.
Functional Screening Service
The ability to display high peptide copy number allows discovery of functional peptides, such as agonists and antagonists, in primary screens
Target Production Services
The Orbit platform is target agnostic giving access to cell surface receptors, notably GPCRs and ion channels. We have a dedicated team focused on production of targets to ensure quality of starting materials
Single Cell Reporter Assay Services
Using expertise in cell line development and assay development, in conjunction with FACS, high content imaging and microfluidics, the Orbit platform can distinguish a functional response from single cells